Literature DB >> 8669491

Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.

T A Järvinen1, J Kononen, M Pelto-Huikko, J Isola.   

Abstract

The role of molecular markers predicting the response to cytotoxic chemotherapy is not established. A potential predictive factor, topoisomerase IIalpha, is a target for certain cytotoxic drugs, and its concentration has been shown to correlate with chemosensitivity in vitro. We evaluated expression of topo IIalpha immunohistochemically in 230 breast cancer samples and studied its association with known clinicopathological factors and factors previously shown to predict response to cytotoxic drugs. Topo IIalpha protein expression was found in 0.6 to 39.4% (10.6 +/- 7.9%, mean +/- SD) of breast carcinoma cells, whereas expression was undetectable in nonmalignant breast epithelium. Topo IIalpha protein expression correlated well with semi-quantitative mRNA in situ hybridization (P = 0.007). A significant association was found between the proportion of topo-IIalpha-positive cells and low estrogen and progesterone receptor content (P<0.0001), high grade (P<0.0001), DNA aneuploidy (P=0.003), and c-erbB-2 oncoprotein overexpression (P<0.0001). Topo IIalpha expression was not associated with clinical variables, such as age of the patient, primary tumor size, or axillary nodal status. A highly significant linear correlation was found between topo IIalpha and tumor proliferation rate (S-phase fraction, r=0.46; P<0.0001). Because hormone receptors, grade, and ploidy are associated with tumor proliferation rate, topo IIalpha expression was adjusted for S-phase fraction to reveal the proliferation-independent clinopathological associations. According to the analysis of co-variance, only aneuploidy (P=0.0003) and c-erb-2 overexpression (P=0.01) were associated with proliferation-adjusted expression of topo IIalpha. In conclusion, the close association of Topo IIalpha with other potential predictive factors (tumor proliferation rate, c-erbB-2 oncoprotein) suggests that topo IIalpha, having a defined role as a target for cytotoxic drugs, may be a valuable predictor of response to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8669491      PMCID: PMC1861630     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

1.  DNA topoisomerase II alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2.

Authors:  S Taagepera; P N Rao; F H Drake; G J Gorbsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

2.  Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22.

Authors:  M Tsai-Pflugfelder; L F Liu; A A Liu; K M Tewey; J Whang-Peng; T Knutsen; K Huebner; C M Croce; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

3.  Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins.

Authors:  S M Davies; C N Robson; S L Davies; I D Hickson
Journal:  J Biol Chem       Date:  1988-11-25       Impact factor: 5.157

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20.

Authors:  W N Keith; F Douglas; G C Wishart; H M McCallum; W D George; S B Kaye; R Brown
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

6.  A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1.

Authors:  H Kreipe; H J Heidebrecht; S Hansen; W Röhlk; M Kubbies; H H Wacker; M Tiemann; H J Radzun; R Parwaresch
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

7.  Tritiated thymidine labeling index and response in human breast cancer.

Authors:  A Sulkes; R B Livingston; W K Murphy
Journal:  J Natl Cancer Inst       Date:  1979-03       Impact factor: 13.506

8.  Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity.

Authors:  O P Kallioniemi
Journal:  Cytometry       Date:  1988-03

9.  Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy.

Authors:  Y Remvikos; P Beuzeboc; A Zajdela; N Voillemot; H Magdelénat; P Pouillart
Journal:  J Natl Cancer Inst       Date:  1989-09-20       Impact factor: 13.506

10.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

View more
  27 in total

Review 1.  AN OVERVIEW OF PROGNOSTIC MARKERS IN BREAST CANCER.

Authors:  G U Deshpande; Ramji Rai
Journal:  Med J Armed Forces India       Date:  2017-06-26

2.  Topoisomerase II alpha and II beta expression in childhood acute lymphoblastic leukaemia: relation to prognostic factors and clinical outcome.

Authors:  A J Lodge; A G Hall; M M Reid; G G McIntosh; M Steward; J J Anderson; C H Horne; B Angus
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

3.  Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

Authors:  T A Järvinen; M Tanner; V Rantanen; M Bärlund; A Borg; S Grénman; J Isola
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 4.  Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

Authors:  Atocha Romero; Trinidad Caldés; Eduardo Díaz-Rubio; Miguel Martín
Journal:  Clin Transl Oncol       Date:  2012-03       Impact factor: 3.405

5.  CORRELATIONSHIP OF CATHEPSIN D AND TOPOISOMERASE II ALPHA WITH NUCLEAR GRADING IN BREAST CANCERS.

Authors:  Prabal Deb; G U Deshpande
Journal:  Med J Armed Forces India       Date:  2011-07-21

6.  Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer.

Authors:  T A Järvinen; M Pelto-Huikko; K Holli; J Isola
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

7.  The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells.

Authors:  Kristine Kleivi Sahlberg; Vesa Hongisto; Henrik Edgren; Rami Mäkelä; Kirsi Hellström; Eldri U Due; Hans Kristian Moen Vollan; Niko Sahlberg; Maija Wolf; Anne-Lise Børresen-Dale; Merja Perälä; Olli Kallioniemi
Journal:  Mol Oncol       Date:  2012-11-24       Impact factor: 6.603

8.  Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.

Authors:  J J Bower; G F Karaca; Y Zhou; D A Simpson; M Cordeiro-Stone; W K Kaufmann
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

9.  Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.

Authors:  Mehmet Salih Iyikesici; Gul Basaran; Faysal Dane; Meltem Ekenel; P Fulden Yumuk; Devrim Cabuk; Mehmet Teomete; N Serdar Turhal
Journal:  Int J Clin Exp Med       Date:  2014-05-15

10.  Extra copies of chromosomes 16 and X in invasive breast carcinomas are related to aggressive phenotype and poor prognosis.

Authors:  Lydia Nakopoulou; Effie G Panayotopoulou; Ioanna Giannopoulou; Ioanna Tsirmpa; Sophia Katsarou; Eleni Mylona; Paraskevi Alexandrou; Antonios Keramopoulos
Journal:  J Clin Pathol       Date:  2007-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.